### The Adrenal Glands

The aim of this presentation is to:

- 1) highlight some of the fundamentals thought in the basic sciences modules to
- facilitate a better understanding of the strategies adopted in clinical medicine when investigating the functions of the adrenal glands.

The referenced general internal medicine textbook is: Chapter 342 'Disorders of the Adrenal Cortex' and chapter 343 'Pheochromocytoma' in: Longo DL, Fauci AS, Kasper DL, Hauser SL, Jameson JL, Loscalzo J. Harrison's Principle of Internal Medicine. 18 ed. McGraw-Hill Professional; 2011.

NB. If no reference appears on a slide the general reference is *Harrison's Principle of Internal Medicine*.

The Investigations of the Adrenal Glands Essential for understanding this presentation:

- 1) Anatomy: The Adrenal Glands and their surroundings
- 2) **Biochemistry:** Hormones produced by the Adrenal Gland
- 3) **Physiology:** Function of the hormones produced by the Adrenal Gland


First then can one start on a journey to investigate abnormal functions of the Adrenal gland

The Investigations of the Adrenal Glands Objectives:


- 1) Describe the mechanisms of endocrine **hypofunction** and **hyperfunction**.
- 2) Differentiate among **primary**, **secondary** and **tertiary** endocrine disorders.
- 3) Discuss based on the normal physiology the rationale behind the investigations of the functions of the Adrenal Glands.


The Investigations of the Adrenal Glands Essential for understanding the investigations


- 1) Anatomy:
- 2) **Biochemistry:**
- 3) **Physiology:**
- 4) **Diseases**



National Cancer Institute (NCI), Alan Hoofring








Which hormones are produced where ?


Mineralocorticoids (Aldosterone) in zona glomerulosa Glucocorticoids (Cortisol) in primarily zona fasciculata Sex steroids primarily in zona reticularis Catecholamines in the adrenal medulla The Investigations of the Pituitary Gland Essential for understanding the investigations

- 1) Anatomy:
- 2) **Biochemistry:**
- 3) **Physiology:**
- 4) **Diseases**


The structure of the steroid hormones:




The nomenclature of the steroid hormones:



The nomenclature of the steroid hormones:




The nomenclature of the steroid hormones:





The nomenclature of the steroid hormones:


Lets rearrange a little more



The nomenclature of the steroid hormones: What do we have ?








We start by removing the side chain Using the 'Cholesterol side-chain cleavage enzyme' And we have Pregnenolone Note we have now 21 C's



Naming can be confusing




'Cholesterol side-chain cleavage enzyme' is the classical name

In 1992 a more systematic database friendly *Enzyme Nomenclature* was introduced by Nomenclature Committee of the International Union of Biochemistry and Molecular Biology (NC-IUBMB)



### A look at the **IUBMB** nomenclature




Q

# A look at the **IUBMB**

	HO Pregnenolone HO	Cholesterol	
× Norton -	tp://www.biologie.uni-hamburg.de/b-online/kegg/kegg/db/ligan d/enz/1.14.15.6.html ♀ ≧ ♂ × ③ Safe Web ▼ ⑤ Identity Safe ▼ □ ♣ ▼ Page ▼ Safety ▼ Tools ▼ ④ ▼ ♪ ♪ ڲ ⑤ ③	It also gives the reaction, Substrates, products	
ENTRY NAME	EC 1.14.15.6 Cholesterol monooxygenase (side-chain-cleaving) Cholesterol desmolase	and cofactor	
REACTION	Cvtochrome P-450SCC Cholesterol + Reduced adrenal ferredoxin + O2 = Pregnenolon	e +	
	4-Methylpentanal + Oxidized adrenal ferredoxin + H2O		
SUBSTRATE	Cholesterol		
	Reduced adrenal ferredoxin	Note it sives the	
	02	Note it gives the	
PRODUCT	Preqnenolone	known diseases	
	<u>4-Methylpentanal</u>		
	Oxidized adrenal ferredoxin	associated with	
	<u>H20</u>	the enzyme	
COFACTOR	Heme	the enzyme	
COMMENT	A heme-thiolate protein. The reaction proceeds in three stages, with hydroxylation at C-20 and C-22 preceding scission of the side-chain at C-20.		
PATHWAY	PATH: MAP00140 C21-Steroid hormone metabolism		
DISEASE	MIM: 118485 Cytochrome P450, subfamily XIA (cholesterol si	de chain	
	cleavage); Polycystic ovary syndrome with	-	
	hyperandrogenemia (2)		
DBLINKS	University of Geneva ENZYME DATA BANK: <u>1.14.15.6</u> WIT (What Is There) Metabolic Reconstruction: <u>1.14.15.6</u>		

## Naming can be confusing



'Cholesterol side-chain cleavage enzyme' is the classical name


In 1992 a more systematic database friendly *Enzyme Nomenclature* was introduced by Nomenclature Committee of the International Union of Biochemistry and Molecular Biology (NC-IUBMB)

But newer books (i.e. Harrisson's) uses another code CYP21A1



# Naming can be confusing





# But newer books (i.e. Harrisson's) uses another code CYP21A1



### HUGO



### Yes!


The code **CYP21A1** is the **gene symbol** for the gene that codes for the – 'EC 1.14.15.6 / Cholesterol side-chain cleavage enzyme'

The HUGO Gene Nomenclature Committee is the only worldwide authority that assigns standardized nomenclature to human genes.

The HGNC approves both a short-form abbreviation (**gene symbol**), and also a longer and more descriptive name. Each symbol is unique and the committee ensures that each gene is only given one approved gene symbol. This allows for clear and unambiguous reference to genes, and facilitates electronic data retrieval from databases and publications. <u>http://www.genenames.org</u>




#### Aldosterone pathway







Adrenal Gland 23






Sample & Assay Technologies







### The Investigations of the Pituitary Gland




Source: Longo DL, Fauci AS, Kasper DL, Hauser SL, Jameson JL, Loscalzo J: Harrison's Principles of Internal Medicine, 18th Edition: www.accessmedicine.com

Copyright © The McGraw-Hill Companies, Inc. All rights reserved.

2011-11-09 ©lassen-nielsen.com

The Investigations of the Pituitary Gland Essential for understanding the investigations

- 1) Anatomy:
- 2) **Biochemistry:**
- 3) **Physiology:**
- 4) **Diseases**




Higher level stimuli


Negative feed- back

Two loops CRH  $\rightarrow$  ACTH  $\rightarrow$  feedback to the hypothalamus

ACTH  $\rightarrow$  circulating free Cortisol  $\rightarrow$  feedback to anterior pituitary and hypothalamus

## Physiology - cortisol circadian rhythm





Remember Aldosterone is controlled by the renin system

Only very little by ACTH

80 – 90% of circulating Cortisol is bound to Cortisol Binding Globulin (CBG) also known as Transcotin. The rest is bound to **albumin** and only a minor fraction circulating as free, unbound hormone. It is believed that it is the free-cortisol that have physiological effect.

Dhillo WS, Kong WM, Le Roux CW et al. Cortisol-binding globulin is important in the interpretation of dynamic tests of the hypothalamic-pituitary-adrenal axis. European Journal of Endocrinology 2002;146(2):231-235.

So what is the effect of a given dose of cortisol. Since it is protein bound would you start with a large dose or a small dose?

If all CBG and albumin in the blood is saturated with cortisol? The amount you administer will be available as free-cortisol =(be effective)

If CBG and albumin in the blood is not saturated with cortisol? The amount you administer will first be used to saturate the proteins and most of the dose might not be available as free-cortisol =(be effective)

1) Dhillo WS, Kong WM, Le Roux CW et al. Cortisol-binding globulin is important in the interpretation of dynamic tests of the hypothalamic-pituitary-adrenal axis. European Journal of Endocrinology 2002;146(2):231-235.

The Investigations of the Pituitary Gland Essential for understanding the investigations

- 1) Anatomy:
- 2) **Biochemistry:**
- 3) **Physiology:**
- 4) **Diseases**

### Hyper - & Hypo-functions of glands

In principle only two things can go wrong:

Increased production (over production) of hormones: <u>Hyper</u>.....dism

Decreased production (under production) of hormones: <u>Hypo</u>.....dism

Of cause there can be many underlying causes: Tumor, starvation, infections ......

## **Glucocorticoid Hormone Excess**


### Typical clinical findings

A note on nomenclature

<u>**Cushing syndrome</u>** refers to the manifestations of hypercortisolism from <u>any</u> cause</u>

<u>**Cushing disease**</u> refers to hypercortisolism from excessive production of ACTH by the pituitary gland

Is Cushing disease a primary / secondary or tertiary disease?



From Porth and Matfin Pathophysiology –Concepts of Altered Health states 2009

## Hyper - ACTH

Hor- mone	Function (Stimulates)	Releasing factors	Hypo function	Hyper – Function	
АСТН	Adrenal cortical hormones	CRH	Second. Adrenal hypofunction	Cushing disease	
MSH	Melanocytes	CRH		Skin pigmentation	
TSH	Thyroid hormone	TRH			
			It is secondary adrenal		
FSH	F: Ovulation, M: Sperm	GnRH	hyperfunction. <u>Cushing Disease</u>		<u>se</u>
LH	Corpus luteum	GnRH	It will be increased production of glucocorticoids from the adrenal		n of
GH	Growth	GHRH			
PRL	Breast feeding		gland.		
ADH	Water reabsorb	Neurogenic	What will be the result of a increased ACTH Production in the		n the
Oxytocin	Uterus Contract	Neurogenic	pituitary gland	d?	

#### **Glucocorticoid Hormone Excess**



Figure 342-8 Clinical features of Cushing's syndrome. A. Note central obesity and broad, purple stretch marks (B. close-up) C. Note thin and brittle skin in an elderly patient with Cushing's. D. Hyperpigmentation of the knuckles in a patient with ectopic ACTH excess.

### **Glucocorticoid Hormone Excess - testing**

Test	Pituitary	Ectopic ACTH	Adrenocortical	
	dependent		Carcinoma	Adenoma
Plasma cortisol morning	Raised or normal	Raised	Raised	Raised or normal
Plasma cortisol evening	Raised	Raised	Raised	Raised
After low-dose dexamethasone	No suppression	No suppression	No suppression	No suppression
After high-dose dexamethasone	Suppressed	No suppression	No suppression	No suppression
Urinary free cortisol	Raised	Raised	Raised	Raised
Plasma ACTH	Raised or normal	Raised	Low	Low

From Crook, Clinical Chemistry and Metabolic Medicine 2006

#### **Clinical suspicion of Cushing's**


Central adiposity, proximal myopathy, striae, amenorrhea, hirsutism, impaired glucose tolerance, diastolic hypertension and osteoporosis


#### Screening/confirmation of diagnosis


- 24-h urine free cortisol excretion increased above normal (3x)
- Dexamethasone overnight test (plasma cortisol > 50nmol/L at 8-9 a.m after 1 mg dexamethasone at 11 p.m.)
- Midnight plasma (or salivary) cortisol > 130 nmol/L


#### If further confirmation is needed/desired:


Low dose DEX test (plasma cortisol > nmol/L after 0.5 mg dexamethasone q6h for 2 days)














#### A. normal

- B. bilateral
  hyperplasi in
  Cushing's
  disease
- C. right adenoma = Cushing's syndrome
- D. Bilateral adenoma = Cushing's syndrome

#### **Glucocorticoid Hormone Excess - testing** The ultimate test: Combining imaging and blood test





25-year-old woman with Cushing's disease.

50-year-old man with Cushing's disease.

Bilateral inferior petrosal sinuses sampling (BIPSS): this test may be required to separate pituitary from ectopic causes of ACTH-dependent Cushing's syndrome in patients with a normal pituitary gland on brain MRI scan.

Kaskarelis IS, Tsatalou EG, Benakis SV, Malagari K, Komninos I, Vasiliadou D et al. Bilateral Inferior Petrosal Sinuses Sampling in the Routine Investigation of Cushing's Syndrome: A Comparison with MRI. American Journal of Roentgenology 2006; 187(2):562-570.

A note on nomenclature

# <u>Conn's syndrome</u> refers to primary hyperaldosteronism

Symptoms: Hypertension, hypokalemia and kaliuria

#### **Clinical suspicion of mineralocorticoid excess**

Severe hypertension (>3 BP drugs, drug-resistant) or Hypokalemia (spontaneous or diuretic-induced) or Adrenal mass or Family history of early-onset hypertension or cerebrovascular events at ,40 years of age

#### Screening


Measurement of aldosterone-renin ratio (ARR) on current blood pressure medication (stop spinrolactone for 4 weeks) and with hypokalemia corrected (AAR screen positive if ARR >750 pmol/L : ng/ml/h and aldosterone > 450 pmol/l) ( consider repeat off ß-blockers for 2 weeks if results are equivocal)


**Rare: Both PRA and aldosterone suppressed** 

24-h urinary steroid profile (gas-chromatography /mass spectrometry

#### **Diagnostic for**

1) Apparant mineralocorticoid excess (HSD11B2 deficiency), 2) CAH(CYP11B1 or CYP17A1 deficiency), 3) Adrenal tumor-related desoxycorticosterone excess If negative, consider Liddle's syndrome (ENaC mutations) (responsive to amiloride trial)






Hyperpigmentation: Skin (bronze tone) Body creases, nipples, And mucous membranes

Loss of weight: Emaciation, anorexia vomiting, and diarrhea

Hypoglycemia Poor tolerance to stress, fatigue muscle weakness



Cardiac insufficiency, hypotension

Adrenal atrophy, destruction

Urinary losses, sodium, water

Retention of potassium

#### Note:

primary adrenocortical hypofunction = Addison's disease.

# Hypo - ACTH

Hor- mone	Function (Stimulates)	Releasing factors	Hypo function		
ACTH	Adrenal cortical hormones	CRH	Second. Adrenal hypofunction		
MSH	Melanocytes	CRH			
TSH FSH	Thyroid hormone F: Ovulation, M: Sperm	TRH GnRH	It will be decrea glucocorticoids gland.	•	
LH	Corpus luteum	GnRH <b>Г</b>			
GH	Growth	GHRH	What will be th decrease ACTH		he
PRL	Breast feeding		pituitary gland?		

ADH	Water reabsorb	Neurogenic		
Oxytocin	Uterus Contract	Neurogenic		


Findings	Primary	Secondary
Anorexia and weight loss	Yes 100%	Yes 100%
Fatigue and weakness	Yes 100%	Yes 100%
Gastrointestinal symptoms, nausea, diarrhea	Yes 50%	Yes 50%
Myalgia, arthralgia, abdominal pain	Yes 10%	Yes 10%
Orthostatic hypotension	Yes	Yes
Hyponatremia	Yes 85-90%	Yes 60%
Hyperkalemia	Yes 60-65%	No
Hyperpigmentation	Yes >90	No
Secondary deficiencies of testosterone, GH, thyroxin, ADH	No	Yes
Associated autoimmune conditions	Yes	No

From Porth and Matfin Pathophysiology – Concepts of Altered Health states 2009


Findings	Primary	Secondary
Anorexia and weight loss	Yes 100%	Yes 100%
Fatigue and weakness	Yes 100%	Yes 100%
Gastrointestinal symptoms, nausea, diarrhea	Yes 50%	Yes 50%
Myalgia, arthralgia, abdominal pain	Yes 10%	Yes 10%
Orthostatic hypotension	Yes	Yes
Hyponatremia	Yes 85-90%	Yes 60%
Hyperkalemia	Yes 60-65%	No
Hyperpigmentation	Yes >90	No
Secondary deficiencies of testosterone, GH, thyroxin, ADH	No	Yes
Associated autoimmune conditions	Yes	No

Why is the symptoms at the top the same in both primary and secondary insufficiency?

Why is the symptoms at the bottom different in primary and secondary insufficiency? What would the symptoms be in tertiary insufficiency?




# Suspected Adrenal insufficiency





# Suspected Adrenal insufficiency

#### **Primary adrenal insufficiency**



### Suspected Adrenal insufficiency






Pheochromocytomas and paragangliomas are catecholamine producing tumors derived from the sympathetic or parasympathetic nervous system

Symptoms are variable. Pheochromocytoma has been termed the "the great masquerade" The classic triad: episodes of palpitations, headaches and profuse sweating accompanied with hypertension makes pheochromocytoma likely.

- Headaches
- Sweating attacks
- Palpitations and tachycardia
- Hypertension, sustained or paroxysmal
- Anxiety and panic attacks
- Pallor
- Nausea
- Abdominal pain

- Weakness
- Weight loss
- Paradoxical response to antihypertensive drugs
- Polyuria and polydipsia
- Constipation
- Orthostatic hypotension
- Dilated cardiomyopathy
- Erythrocytosis
- Elevated blood sugar
- Hypercalcemia



Diagnostic method		Sensitivity	Specificity
24 hour urinary	VanillyImandelic acid(VMA)	++	++++
tests	Catecholamines	+++	+++
	Fractional metanephrines	++++	++
	Total metanephrines	+++	++++
Plasma tests	Catecholamines	+++	++
	Free metanephrines	++++	+++
	Picture	++++	+++
	MIGB scintigraphy	+++	++++
	Somatostatin receptor scintigraphy	++	++
	DOPA (dopamine) PET positron emission tomography	+++	++++